Wockhardt Share Surges 19% as USFDA Accepts New Drug Filing
Wockhardt share soared by 19% on Tuesday as the US Food and Drug Administration (USFDA) accepted the company’s new drug application (NDA) for its breakthrough antibiotic, Zaynich. This development marks a significant milestone for Wockhardt, one of India’s leading pharmaceutical companies, highlighting its growing presence in the global market.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
